Investors Sue Over Lilly's $960M Buy Of Migraine Drug Co.
About two weeks after Eli Lilly & Co. announced it was buying migraine treatment developer CoLucid Pharmaceuticals Inc. for $960 million, a CoLucid investor sued Friday in Massachusetts federal court, alleging...To view the full article, register now.
Already a subscriber? Click here to view full article